Publicaciones en colaboración con investigadores/as de Universidad de Granada (42)

2024

  1. Insights into the pathogenesis of primary hyperoxaluria type I from the structural dynamics of alanine:glyoxylate aminotransferase variants

    FEBS Letters, Vol. 598, Núm. 4, pp. 485-499

2023

  1. Counterintuitive structural and functional effects due to naturally occurring mutations targeting the active site of the disease-associated NQO1 enzyme*

    FEBS Journal, Vol. 290, Núm. 7, pp. 1855-1873

2022

  1. Allosteric Communication in the Multifunctional and Redox NQO1 Protein Studied by Cavity‐Making Mutations

    Antioxidants, Vol. 11, Núm. 6

  2. Different phenotypic outcome due to site-specific phosphorylation in the cancer-associated NQO1 enzyme studied by phosphomimetic mutations

    Archives of Biochemistry and Biophysics, Vol. 729

  3. Effect of naturally-occurring mutations on the stability and function of cancer-associated NQO1: Comparison of experiments and computation

    Frontiers in Molecular Biosciences, Vol. 9

  4. Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias

    Bioorganic Chemistry, Vol. 129

  5. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production

    European Journal of Medicinal Chemistry, Vol. 237

  6. Phosphorylation of Thr9 Affects the Folding Landscape of the N-Terminal Segment of Human AGT Enhancing Protein Aggregation of Disease-Causing Mutants

    Molecules (Basel, Switzerland), Vol. 27, Núm. 24

  7. Targeting HIF-1α Function in Cancer through the Chaperone Action of NQO1: Implications of Genetic Diversity of NQO1

    Journal of Personalized Medicine, Vol. 12, Núm. 5

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  2. Small molecule-based enzyme inhibitors in the treatment of primary hyperoxalurias

    Journal of Personalized Medicine, Vol. 11, Núm. 2, pp. 1-31

  3. Structural basis of the pleiotropic and specific phenotypic consequences of missense mutations in the multifunctional NAD(P)H:quinone oxidoreductase 1 and their pharmacological rescue

    Redox Biology, Vol. 46

2020

  1. Naturally-occurring rare mutations cause mild to catastrophic effects in the multifunctional and cancer-associated NQO1 protein

    Journal of Personalized Medicine, Vol. 10, Núm. 4, pp. 1-31

2019

  1. A dynamic core in human NQO1 controls the functional and stability effects of ligand binding and their communication across the enzyme dimer

    Biomolecules, Vol. 9, Núm. 11

  2. Insight into the specificity and severity of pathogenic mechanisms associated with missense mutations through experimental and structural perturbation analyses

    Human Molecular Genetics, Vol. 28, Núm. 1, pp. 1-15

  3. Structural and functional insights on the roles of molecular chaperones in the mistargeting and aggregation phenotypes associated with primary hyperoxaluria type I

    Advances in Protein Chemistry and Structural Biology (Academic Press Inc.), pp. 119-152

  4. Systemic Alanine Glyoxylate Aminotransferase mRNA Improves Glyoxylate Metabolism in a Mouse Model of Primary Hyperoxaluria Type 1

    Nucleic Acid Therapeutics, Vol. 29, Núm. 2, pp. 104-113

2018

  1. Evolutionary divergent suppressor mutations in conformational diseases

    Genes, Vol. 9, Núm. 7

  2. Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer

    Handbook of Experimental Pharmacology (Springer New York LLC), pp. 155-190

  3. Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1

    Journal of Medicinal Chemistry, Vol. 61, Núm. 16, pp. 7144-7167